Although several HCV drugs can cure almost all infections regardless of viral genotype, picking the right drug will depend on each patient's medical history, level of liver damage, and coinfections.
As With HIV, New York State Was Set to Lead the Nation to End Hepatitis C. But Why Haven’t the Recommendations Been Made Public?
Activist and member of the state task force Annette Gaudino would like the public to know.
IPERGAY scientists recommended that clinicians screen patients who request PrEP, as well as patients who are already using it, for a number of key HCV risk factors.
The HIV services organization Housing Works implemented a hepatitis C treatment program in New York City, with very high completion rates.
Montreal scientists found that 88% of cannabis users had an undetectable viral load. This suggests that a very large majority of cannabis users did not have problems adhering to antiretroviral therapy.
A series of studies aim to determine whether test-and-treat strategies can be implemented for people with hepatitis C, much like programs for people living with HIV.
An in-depth update on what we know about HCV risk, symptoms, screening, outcomes, and treatment (including financial barriers).
A new study puts numbers to increasingly divergent trends in liver-related deaths vs. injection-related deaths in recent years, highlighting both the success of modern HCV treatment and the devastating effects of the opioid crisis.
The 548-person U.S. study found that chronic hepatitis C infection occurred among an identical number of people who received the experimental vaccine compared to people who received a placebo.
Two models, one from Washington State and another from Los Angeles County, can be duplicated elsewhere to get people into care, experts say.
"Providing HCV treatment alone while neglecting to concurrently address the social determinants of health will do little to improve the health outcomes of the majority of individuals with chronic HCV," the study authors wrote.